Eric Hwang advises global public and private technology and life sciences clients on diverse strategic transactions, including complex cross-border mergers and acquisitions (M&A), corporate governance matters, joint ventures, and corporate and venture capital, private equity, and corporate investments. Drawing from a background in both in-house, business-side leadership and private practice roles, Eric has a deep understanding of the type and scope of services that companies seek from outside advisors. Over the course of his career, he has completed more than 80 transactions, representing an aggregate value of more than $30 billion.
Eric’s experience with strategic matters, financial analysis, and business operations allows him to quickly adjust to ever-changing situations and provide practical advice and business-minded solutions to a myriad of complex issues.
Before joining Morgan Lewis, Eric was a partner in the corporate and M&A practice of another global law firm, and prior to that spent several years at an international law firm where he represented technology, pharmaceutical, and healthcare clients in M&A and other strategic transactions.
Prior to reentering private practice, Eric worked first as senior counsel and then as director of corporate development at Oracle Corporation, a global enterprise technology company. In his roles at Oracle, Eric held responsibility for all aspects of the company’s acquisitions, and played a key role in the acquisitions of BEA Systems and Sun Microsystems, as well as other acquisitions of public companies. Eric was also an early and key contributor to Oracle's M&A program, establishing practices that have since been used in more than 100 acquisitions.
As both a business and legal leader in Oracle's many acquisitions throughout his tenure, Eric played an important role in helping M&A become one of Oracle’s strategic drivers of growth, with annual revenue growing $19 billion from 2007 to 2012.
Advised Gilead Sciences, Inc. (NASDAQ: GILD), a research-based biopharmaceutical company, in various transactions, including its sales of its spleen tyrosine kinase inhibitor portfolio to Kronos Bio, Inc. (NASDAQ: KRON), a clinical-stage biopharmaceutical company focused on cancer therapeutics, GS-6637 and related assets to Amygdala Neurosciences, Inc., a biopharmaceutical company focused on addiction disorders and its collaboration agreement valued up to $1.5 billion with Scholar Rock Holding (NASDAQ: SRRK) for the development and commercialization of Scholar Rock’s novel therapies for fibrotic diseases.
Advised Intel Corporation (NASDAQ: INTC) in multiple acquisitions, strategic transactions and investments spanning a wide variety of technologies and applications, including its investments in Sierra Private Investments L.P., the controlling shareholder of Mavenir plc and Ozon Holdings plc (MCX: OZON), its acquisition of substantially all of the assets related to the mobile phone chipset business of an Asian telecommunications company, its acquisition of a European provider of over-the-air software update technology and in connection with its Emerging Growth & Incubation (EGI) program.
Advised CapitalG, Alphabet Inc.'s (NASDAQ: GOOGL) growth equity investment fund, in various investments, including its acquisition of a minority stake in private equity firm TPG's acquisitions of RCN Telecom Services LLC and Grande Communications Networks LLC, two cable providers.
Advised Oracle Corporation (NYSE: ORCL), a global enterprise technology company, in its acquisition of Talari Networks, a provider of Software-Defined Wide area Networks, and dozens of other acquisitions involving a wide range of technology products and deployments, including database, middleware, applications, hardware, and on-premise and SaaS.
Represented Samsung across a variety of its businesses in connection with various strategic transactions and other corporate matters, including several technology portfolio company exits.
Advised Pivotal Software, Inc. (NYSE: PVTL), a subsidiary of VMware (NYSE: VMW) and a data and analytics software and services provider, in multiple transactions, including its UK-based acquisitions of Cloud Credo Ltd., a Cloud Foundry development and services provider, and StayUp.IO, a provider of software tools in the Cloud Foundry log analysis space, and its joint venture with Telstra Corporation Limited (ASX: TLS), one of Australia's largest telecommunications and media companies.
Advised Parade Technologies (Taipei Exchange: 4966 TWO), a supplier of video display and interface integrated circuits, in its acquisition of Fresco Logic, a fabless semiconductor company, for $37.5 million.
Advised Khazanah Nasional Berhad, the sovereign wealth fund of Malaysia, in numerous investments, including its investment in Palantir.
Represented GN Store Nord A/S (Denmark), a hearing aid manufacturer, in its acquisition of the membership interests in and related commercial matters with NationsBenefits, LLC, a distributor of state-of-the-art hearing aids and other hearing loss solutions.
Represented Vidder, Inc., a cybersecurity company, in the sale of its PrecisionAccess™ solution and other Software Defined Perimeter (SDP) related assets to Verizon.
Advised BrightEdge, an SEO and content marketing company, in its M&A and strategic transactions, including its acquisition of certain assets of Captora.
Advised B. Riley FBR Inc., as the financial adviser in its issuance of a fairness opinion in connection with the merger between Glowpoint Inc., a managed service provider of video collaboration and network applications, and SharedLabs Inc., a privately held software and technology services company.
Advised a leading listed technology company in its investment in a machine learning company.
Advised Clarizen, an enterprise project portfolio management software provider, in its sale to K1 Investment Management, for over $100 million USD.
Advised Voltage Security, Inc., a provider of data-centric encryption and tokenization technology, in its sale to Hewlett-Packard Company (NYSE: HPE), an American multinational information technology company.
Advised Merck KGaA (XETRA: MRK), a German chemical and pharmaceutical company and a life sciences business, and Merck Millipore, its life sciences business, in its acquisition of worldwide rights to a molecule counting technology from Singulex Inc.
Advised AIXTRON SE (NASDAQ: AIXG), a leading manufacturer of deposition systems for the semiconductor industry, in its acquisition of PlasmaSi, Inc., a provider of OLED encapsulation technology.
Advised NTT Communications, the ICT solutions and international communications business within the Nippon Telegraph & Telephone Corporation (NYSE: NTT), in its acquisition of RagingWire Data Centers, a provider of data center co-location services.
Advised Armorize Technologies, Inc., a provider of cloud-based threat and malware detection technology, in its sale to Proofpoint (NASDAQ: PFPT), a provider of security-as-a-service software.
Advised a global provider of software and custom development services on several complex, multijurisdictional, strategic transactions.
Advised Synder Filtration, a US membrane technology company, in its establishment of various joint ventures to develop certain membrane technologies with a multinational chemical company.
University of California, Los Angeles School of Law, 2003, J.D.
University of California, San Diego, 2000, B.A., Political Science, with an emphasis on International Relations with a double minor in Economics and Chinese Studies
Awards and Affiliations
Recommended, Industry focus: Healthcare: life sciences, The Legal 500 US (2019)
Recommended, M&A/Corporate and Commercial: M&A: Middle-Market ($500m–999m), The Legal 500 US (2017)
Recommended, M&A/Corporate and Commercial: Venture Capital and Emerging Companies, The Legal 500 US (2017)